EXECUTIVE LEADERSHIP TEAM
David J. Mazzo, Ph.D.
Chief Executive Officer
David J. Mazzo, Ph.D., joined Regado Biosciences in August 2008 as President and Chief Executive Officer. Dr. Mazzo brings to Regado almost 25 years of experience in the pharmaceutical industry, most recently as President and CEO of Æterna Zentaris. Dr. Mazzo also has served as President and CEO of Chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group, after holding senior management and executive positions in R&D at Schering-Plough, Hoechst Marion Roussel and Rhone-Poulenc Rorer.
Dr. Mazzo is a pharmaceutical executive and strategic leader with broad technical and managerial experience gained from working in a variety of multicultural and multilingual environments in the USA, Canada, Europe and Asia. He is recognized for his strong strategic, scientific and regulatory expertise, upon which he has amassed a track record of approximately 25 years of successful global product development, registration and launch. Dr. Mazzo has proven himself to be a change leader uniquely adept at driving working groups to new levels of performance and achievement.
Dr. Mazzo currently is Non-Executive Chairman of pSivida, Inc., and a Director of Avanir Pharmaceuticals. He earned a Bachelor of Arts degree in the Honors Program (Interdisciplinary Humanities) and a Bachelor of Science degree in Chemistry from Villanova University. In addition, Dr. Mazzo received his Master of Science degree in Chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.
Michael A. Metzger, MBA
President and Chief Operating Officer
Michael A. Metzger joined Regado in December 2013 as President and Chief Operating Officer. Mr. Metzger has nearly 20 years of experience within the life sciences and pharmaceuticals industries. Mr. Metzger has a distinguished track record of building value for shareholders through product and company acquisitions as well as organic growth by leveraging pharmaceutical partnerships.
Prior to joining Regado, from April 2011 to November 2013, Mr. Metzger held the position of Executive Vice President and Chief Operating Officer at Mersana Therapeutics, a private, venture-financed, biopharmaceutical company developing next generation antibody drug conjugates for oncology. At Mersana, he established key business alliances and helped architect the strategic direction, financing and growth of the business which led to Mersana being named a Fierce15 Biotech Company in 2012. Prior to joining Mersana in early 2011, Mr. Metzger held senior positions within Business Development and led Mergers and Acquisitions at Forest Laboratories, Inc. where he completed deals with numerous specialty pharmaceutical and biotechnology companies including Cerexa, Novexel, Ironwood Pharmaceuticals and Clinical Data, Inc.
Prior to his time at Forest, Mr. Metzger was Vice President Corporate Development at Onconova Therapeutics, Inc., from 2001 until 2006. At Mesa Partners, Inc., a venture capital firm from 1997 to 2001, he was Managing Director. Mr. Metzger served as a member of the Board of Directors of Response Genetics, Inc., a company focused on the development and commercialization of molecular diagnostic tests for cancer from 2010 to November 2013. Mr. Metzger holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.
Steven L. Zelenkofske, D.O., F.A.C.C.
Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
Steven L. Zelenkofske, D.O., F.A.C.C. joined Regado in December 2008 as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer. Dr. Zelenkofske has led clinical programs for 15 development-stage and commercialized cardiovascular products during his pharmaceutical career and has extensive experience as a principal investigator on a number of important trials in cardiovascular medicine.
Most recently, Dr. Zelenkofske served as Vice President, Cardiovascular/Thrombosis Medical Unit – US at Sanofi-Aventis Pharmaceuticals and, prior to this, as Vice President of Clinical Sciences and Chief Patient Safety Officer for Boston Scientific Corporation’s Cardiac Rhythm Management (CRM) Group. At both companies, Dr. Zelenkofske led the development and implementation of cardiovascular pre- and post-market clinical strategy. Prior to this, he was a senior director with Novartis Pharmaceuticals, where he held positions of increasing responsibility within its cardiovascular division, attaining the position of Senior Medical Director, US Clinical Development, Hypertension and CV Section Head. Dr. Zelenkofske also served as Director of CV Research and Clinical Director of Electrophysiology Laboratory at the Heart Care Group, where he was a physician investigator for a number of pivotal cardiovascular clinical trials, including SCD HeFT, COMPANION, MADIT, AVID and MUSTT.
Dr. Zelenkofske is the author or co-author of numerous articles published in professional journals, including the New England Journal of Medicine, Circulation, American Heart Journal and the European Heart Journal. He is a practicing electrophysiologist at Lehigh Valley Hospital in Allentown, Pennsylvania, and serves as an associate professor of medicine at the College of Medicine of the Pennsylvania State University/Hershey Medical Center and for the Philadelphia College of Osteopathic Medicine. Dr. Zelenkofske earned Bachelor of Science and Master’s degrees in biochemistry and immunopharmacology at Emory University. He received a medical degree from the Philadelphia College of Osteopathic Medicine and holds certifications in clinical cardiac electrophysiology, cardiology and internal medicine.
Nicholas J. Pelliccione, Ph.D.
Senior Vice President of Regulatory Affairs and Quality Assurance
Nicholas Pellicione joined Regado as our Senior Vice-President, Regulatory Affairs and Quality Assurance in May 2014.Prior to joining the Company, from May 2007 to March 2014, Dr. Pelliccione served as Senior Vice President, Regulatory Affairs and Quality Assurance of Aeterna Zentaris Inc., a publicly traded biopharmaceutical company. At Aeterna Zentaris Inc., Dr. Pelliccione was responsible for the clinical/preclinical and CMC regulatory aspects of new drugs in the oncology and endocrinology therapy areas, in addition to having responsibility for Quality Assurance.
From May 2005 until March 2007, he served as Senior Vice President, Regulatory and Pharmaceutical Sciences at Chugai Pharma USA, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. Prior to his experience at Chugai, Dr. Pelliccione spent more than 15 years at Schering Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc., holding positions with increasing responsibility from Manager of Regulatory Affairs, Oncology to Vice President, Global Regulatory Affairs, Chemistry, Manufacturing and Controls. During his time at Schering Plough, Dr. Pelliccione was responsible for clinical/preclinical and CMC regulatory aspects of both new and approved drugs in the oncology, anti-infectives, cytokines, cardiovascular and endocrine therapy areas, leading to several approvals. Dr. Pelliccione holds a Ph.D. in Biochemistry from Mount Sinai School of Medicine, New York and a BS in Chemistry from Polytechnic University.
Chris Rusconi, Ph.D.
SVP Discovery/Preclinical Development and Chief Scientific Officer
Chris Rusconi Ph.D. is a co-founder of Regado and serves as the Company’s Chief Scientific Officer.
Prior to joining Regado in 2003, Dr. Rusconi was Director of Research for the Program in Combinatorial Therapeutics and Assistant Research Professor of Surgery at Duke University Medical Center. As Director of Research, he focused on the discovery and early development of nucleic acid-based therapeutics by integrating input from leading clinicians with the technologic know-how of basic and translational scientists. Dr. Rusconi has authored or co-authored more than 20 peer-reviewed publications, including works appearing in Nature, Circulation and the Journal of Clinical Investigation. He is the co-inventor of the Regado technology and the Company’s lead program, the REG1 Anticoagulation System, and has led the development of this program from discovery into phase 2 testing.
Dr. Rusconi earned a Bachelor of Science degree in the Honors Program in Cellular Biology from the University of Kansas, and a Ph.D. in Molecular and Cellular Biology from the University of Colorado, Boulder. He continued his training as a Jane Coffin Childs postdoctoral fellow at Duke University Medical Center.
Don Elsey, MBA
Senior Vice President, Finance and Chief Financial and Compliance Officer
Don Elsey joined Regado in May 2014 as Senior Vice President, Finance and Chief Financial Officer. Prior to joining the Company, from December 2012 to February 2014 Mr. Elsey served as chief financial officer of LifeCell, Inc., a privately held regenerative medicine company. From June 2005 to December 2012, he served in numerous finance capacities, most recently as senior vice president and chief financial officer, at Emergent BioSolutions Inc., a publicly held biopharmaceutical company.
He served as the director of finance and administration at IGEN International, Inc., a publicly held biotechnology company, and its successor BioVeris Corporation, from April 2000 to June 2005. Prior to joining IGEN, Mr. Elsey served as director of finance at Applera, a genomics and sequencing company, and in several finance positions at International Business Machines, Inc. Mr. Elsey serves on the board of directors of RegeneRx Biopharmaceuticals, a publicly traded biopharmaceuticals company. He received an M.B.A. in finance and a B.A. in economics from Michigan State University. Mr. Elsey is a certified management accountant.